Moving boxes surrounded Kim Rejndrup in his new Florida home shortly after he joined OmniComm Systems, Inc. as senior vice president of Product Development. It was a 1,470-mile career move from Boston, where he had spent nearly 20 years at Oracle Corporation as vice president of Development for many of Oracle’s clinical research applications, including systems for electronic data capture (EDC), clinical trial management, data management, medical coding and data warehousing.

(This is the third of a three-part series* on medical coding during clinical trials.)

(This is the second of a three-part series* about medical coding during clinical trials.)

(This is the first of a three-part series on medical coding during clinical trials.)

On the last Friday of May 2018, the General Data Protection Regulation (GDPR) took effect in Europe and generated headlines around the globe. GDPR was enacted to unify and fortify the protection of personal data for all EU residents. The regulation applies to all companies that conduct business within the EU and includes the export of personal data beyond EU borders.

There are more than 270,000 clinical studies underway in all 50 states of the U.S. and in 203 countries, according to the U.S. National Library of Medicine (ClinicalTrials.gov).

Did you know? About 4,000 clinical research employees in Germany have a valuable voice in the life sciences industry thanks to The Federal Association of Contract Research Organisations, (Bundesverband Medizinischer Auftragsinstitute, BVMA e.V.). Founded in July 1991, BVMA represents contract research organizations (CROs) based in German-speaking countries.

Not long ago, clinical trials involved 100% onsite monitoring in an effort to ensure high data quality. But how effective and efficient was that process? Several analyses have shown that only 1-2% of data is corrected as a result of source data verification (SDV). Therefore, the concept of risk-based monitoring (RBM) was born. The goal was to complete a more targeted monitoring (<100% SDV) without compromising patient safety or data quality.

It’s not inexpensive to develop a new drug or medical device. In 2016, bio/pharma companies spent approximately $127 billion on research and development. By 2020, R&D expenditures are estimated at $148 billion globally, according to PharmSource Information Services, a leading research and news outlet.